Brain Tumor Res Treat.  2016 Oct;4(2):138-141. 10.14791/btrt.2016.4.2.138.

A Case of Solitary Brain Metastasis from Uterine Mullerian Adenosarcoma with Sarcomatous Overgrowth

• Hong SB
• Kim MJ
• Kwon JY
• Choi SJ
• Kim EY
• Lim J

• KMID: 2356984
• DOI: http://doi.org/10.14791/btrt.2016.4.2.138

Abstract

Uterine adenosarcoma (AS) are rare tumors and have more favorable outcomes than the aggressive uterine carcinosarcomas. Uterine adenosarcoma with sarcomatous overgrowth (ASSO) is a variant form of AS and exhibits aggressive growth of tumor and the prognosis is relatively poor compared with typical AS. Usually patterns of metastasis have been known to behave like endometrial carcinoma and spread through the lymphatics. Brain metastasis from uterine AS is extremely rare. Herein, we report a case of successfully surgically removed solitary brain metastasis without any extracranial recurrence from uterine ASSO after 4 years of primary treatment.

Keyword

Adenosarcoma of the uterus; Brain; Metastasis

MeSH Terms

Adenosarcoma*
Brain*
Carcinosarcoma
Endometrial Neoplasms
Female
Neoplasm Metastasis*
Prognosis
Recurrence

Figure

• 

  Fig. 1 MRI findings of a solitary brain metastasis from uterine carcinosarcoma. A solitary, necrotic lesion in the leftt central region with a cerebral surrounding edema resulting midline shifting (brain MRI T1 weighted with gadolinium-enhancement image).

• 

  Fig. 2 Uterine adenosarcoma with sarcomatoid epithelial (A) and stromal components are exist and showed sarcomatoid overgrowth (B).

• 

  Fig. 3 A and B: Brain metastasis area exhibits sarcomatous overgrowth having stromal cells displaying obvious cytologic atypia and increased mitotic figures. In immunohistochemical staining, CD10 was positive in glial lesion and negative in tumor lesion (C) and CD34 was positive (D).

Reference

1. Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014; 135:455–461.

2. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116:131–139.

3. Bernard B, Clarke BA, Malowany JI, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013; 131:634–639.

4. Clement PB, Scully RE. Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor. Cancer. 1974; 34:1138–1149.

5. Daskalaki A, Xenaki S, Athanasakis E, Chrysos E, Chalkiadakis G. Advanced mesodermal (Müllerian) adenosarcoma of the ovary: metastases to the lungs, mouth, and brain. Case Rep Surg. 2015; 12. 30. DOI: 10.1155/2015/403431.

6. Sinha A, Phukan JP, Sengupta S, Guha P. Mullerian adenosarcoma of uterus with sarcomatous overgrowth and heterologous component associated with stromal deposit in omentum: a case report and review of the literature. Case Rep Med. 2012; Aug. 16. DOI: 10.1155/2012/820378.

7. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990; 21:363–381.

8. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992; 11:75–88.

9. N'Kanza AL, Jobanputra S, Farmer P, Lovecchio J, Yelon JA, Rudloff U. Central nervous system involvement from malignant mixed Müllerian tumor (MMMT) of the uterus. Arch Gynecol Obstet. 2005; 273:63–68.

10. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol. 2003; 43:61–64.

11. Arici DS, Aker H, Yildiz E, Tasyurt A. Mullerian adenosarcoma of the uterus associated with tamoxifen therapy. Arch Gynecol Obstet. 2000; 264:105–107.

12. Piscuoglio S, Burke KA, Ng CK, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol. 2016; 238:381–388.

13. Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol. 2009; 33:278–288.

14. Major FJ, Blessing JA, Silverberg SG. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993; 71:4 Suppl. 1702–1709.

15. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol. 2001; 83:89–94.

16. Iqbal JB, Ironside JW. Cerebral metastasis from a malignant mixed müllerian tumour of the uterus. Histopathology. 1993; 23:277–279.

17. Cormio G, Colamaria A, Di Vagno G, Pierangeli E, Vailati G, Selvaggi L. Central nervous system involvement secondary to metastatic mixed müllerian tumor of the uterus. Gynecol Obstet Invest. 1997; 44:214–216.

18. Kim JK, Lee SK, Myong NH, Kang YD. Biopsy-proven cerebellar metastasis from a malignant mixed mullerian tumor (MMMT) of the uterus: case report. Eur J Gynaecol Oncol. 2009; 30:196–198.